There are 2789 resources available
1247P - Management of infusion-related reactions (IRRs) in patients receiving amivantamab
Presenter: Keunchil Park
Session: ePoster Display
1431P - Descriptive analysis and prognostic factors of microsatellite instability (MSI) gastric cancer patients (pts) compared to microsatellite stable (MSS) pts in a tertiary hospital
Presenter: Oriol Mirallas
Session: ePoster Display
1356P - Cumulative incidence and baseline imaging patterns of brain metastases in advanced EGFR and ALK positive non-small cell lung cancer (NSCLC)
Presenter: Maisha Chowdhury
Session: ePoster Display
1357P - A deep radiomics approach to assess PD-L1 expression and clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A multicentric study
Presenter: Marion Tonneau
Session: ePoster Display
1358P - Phase I dose-escalation study to evaluate safety and clinical activity of c-MET inhibitor ABN401 in patients with advanced solid tumor
Presenter: Dae Ho Lee
Session: ePoster Display
1359TiP - RELATIVITY-104: First-line relatlimab (RELA) + nivolumab (NIVO) with chemotherapy vs nivo with chemotherapy in stage IV or recurrent non-small cell lung cancer (NSCLC): A phase II, randomized, double-blind study
Presenter: Daniel Morgensztern
Session: ePoster Display
1360TiP - First-line (1L) maintenance therapy with niraparib (nira) + pembrolizumab (pembro) vs placebo + pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study
Presenter: Suresh Ramalingam
Session: ePoster Display
1361TiP - Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02)
Presenter: Egbert F. Smit
Session: ePoster Display
1362TiP - Capmatinib versus docetaxel in pretreated patients with MET exon 14 skipping-mutated locally advanced or metastatic NSCLC: The GeoMETry-III phase III study
Presenter: Pierre-Jean Souquet
Session: ePoster Display
1363TiP - A phase I/II study of TPX-0131, a novel oral ALK tyrosine kinase inhibitor, in patients with ALK+ advanced/metastatic NSCLC
Presenter: Ben Solomon
Session: ePoster Display